Pijuan-Domenech A, Pineda V, Ferreira-Gonzalez I, Marsal JR, Castro Miguel A, Sureda-Barbosa C, Valente F, Miranda B, Subirana-Domenech T, Dos-Subira L, Garcia-Dorado D, Casaldaliga-Ferrer J. Diagnosing abnormal end-diastolic forward flow: new definition proposal based on healthy controls. IJC CHD. 2021 Aug;4:100140. doi: 10.1016/j.ijcchd.2021.100140
Wheeler SB, Kohler RE, Reeder-Hayes KE, Goyal RK, Lich KH, Moore A, Smith TW, Melvin CL, Muss HB. Endocrine therapy initiation among Medicaid-insured breast cancer survivors with hormone receptor-positive tumors. J Cancer Surviv. 2014 Dec;8(4):603-10. doi: 10.1007/s11764-014-0365-3
Henk HJ, Kaye JA, Rothman KJ, Becker LK, Legg JC, Li X. Variation by age in neutropenic complications among patients with cancer receiving chemotherapy. Community Oncol. 2013 Jan 1;10(1):16-26.
Brubaker L, Richter HE, Barber MD, Hsu Y, Rahn DD, Menefee S, Visco A, Spino C, Martin S, Meikle SF. Pelvic floor disorders clinical trials: participant recruitment and retention. Int Urogynecol J. 2013 Jan 1;24(1):73-9.
Hegarty AC, Carsin AE, Comber H. Geographical analysis of cancer incidence in Ireland: comparison of two bayesian spatial models. Cancer Epidemiol. 2010 Aug;34(4):373-81. doi: 10.1016/j.canep.2010.04.019
Oglesby A, Sherif B, Odom D, Leahy M, Qian Y. Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease. Community Oncol. 2009 Nov 1;6(11):494-502.
Buchanan A, Sugg Skinner C, Calingaert B, Schildkraut J, King R, Marcom K. Cancer genetic counseling in rural North Carolina oncology clinics: program establishment and patient characteristics. Community Oncol. 2009;6(2):70-7.